Italy's CDMO Flamma has completed the construction of its first cGMP Kilo Lab at its Chignolo D’Isola Headquarters in Italy. Flamma is a small molecule active pharmaceutical ingredients (APIs) manufacturer for the pharmaceutical industry.
Chignolo is a city in the Province of Bergamo in the Italian region of Lombardy, located about 35 kilometres northeast of Milan.
The cGMP Kilo Lab is currently being used for an internal Flamma project in conjunction with its Flow Chemistry Pilot Unit. Flamma said customers with projects are reserving production slots for later in 2019.
This investment is part of the Flamma 2020 plan to bring improvement across its network of manufacturing facilities. This addition to the Chignolo site adds another option when working with Flamma’s API site.
GianMarco Negrisoli, Flamma Corporate Development Manager and CEO of Flamma Innovation, commented: “The opening of a cGMP kilo lab not only increases capabilities of our facility but also allows our customers greater flexibility in working with Flamma. The ability to place projects in Italy or China and knowing that Flamma is actively managing all our sites is comforting to our customer base.”
Flamma has also announced that construction work for a new R&D building at the Chignolo headquarters is scheduled to commence later this year. Upon completion, the project will quadruple Flamma's R&D space.
Kenneth Drew, Director North America Sales and Business Development, noted that the expansion will allow Flamma to continue to grow the staff of researchers to serve the pharma industry and the demands of our current customers as well as future customers.
“The additional benefit of this addition is the ability to have a fully dedicated analytical building for our growing quality team," Drew said.
In addition to the Bergamo site, the API manufacturer also has a new cGMP workshop at Flamma Honkai, its wholly owned Chinese facility located in Dalian.
